Launch of the S.O.L.V.E-AMR Hub: Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance.

CYNBIOSE, BIOASTER, ICTA and PharmaLex join forces to launch a pioneering initiative to fast-track antimicrobials from R&D to commercialization (S.O.L.V.E-AMR)!

This new strategic collaboration aims at supporting the fight against antimicrobial resistance (AMR). As part of the initiative, the organizations offer innovative and integrated support from discovery, pre-clinical and clinical drug development processes up to registration and commercialization, helping to accelerate the development of antimicrobials.

We are delighted to leverage our complementary expertise and capabilities to support innovative AMR solutions.

Read the press release to learn more about this initiative.

For more information on our AMR capabilities.